These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 21767630)
1. Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. LeCureux L; Cheng CS; Herbst J; Reilly TP; Lehman-McKeeman L; Otieno M Toxicol In Vitro; 2011 Dec; 25(8):1934-43. PubMed ID: 21767630 [TBL] [Abstract][Full Text] [Related]
2. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975 [TBL] [Abstract][Full Text] [Related]
3. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats. Miyamoto S; Matsumoto A; Mori I; Horinouchi A Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005 [TBL] [Abstract][Full Text] [Related]
4. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Atienzar F; Gerets H; Dufrane S; Tilmant K; Cornet M; Dhalluin S; Ruty B; Rose G; Canning M Toxicol Sci; 2007 Mar; 96(1):101-14. PubMed ID: 17175557 [TBL] [Abstract][Full Text] [Related]
5. Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. Tilmant K; Gerets HH; Dhalluin S; Hanon E; Depelchin O; Cossu-Leguille C; Vasseur P; Atienzar FA Toxicol In Vitro; 2011 Oct; 25(7):1414-24. PubMed ID: 21515356 [TBL] [Abstract][Full Text] [Related]
6. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588 [TBL] [Abstract][Full Text] [Related]
7. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Bhandari N; Figueroa DJ; Lawrence JW; Gerhold DL Assay Drug Dev Technol; 2008 Jun; 6(3):407-19. PubMed ID: 18537465 [TBL] [Abstract][Full Text] [Related]
8. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Fujimura H; Dekura E; Kurabe M; Shimazu N; Koitabashi M; Toriumi W Exp Toxicol Pathol; 2007 Aug; 58(6):375-82. PubMed ID: 17408938 [TBL] [Abstract][Full Text] [Related]
9. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Morelli JK; Buehrle M; Pognan F; Barone LR; Fieles W; Ciaccio PJ Cell Biol Toxicol; 2006 Jan; 22(1):15-27. PubMed ID: 16463016 [TBL] [Abstract][Full Text] [Related]
10. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072 [TBL] [Abstract][Full Text] [Related]
11. In vitro validation of drug-induced phospholipidosis. Park S; Choi YJ; Lee BH J Toxicol Sci; 2012; 37(2):261-7. PubMed ID: 22467016 [TBL] [Abstract][Full Text] [Related]
12. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach. Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432 [TBL] [Abstract][Full Text] [Related]
13. From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier. Yang L; Zhong X; Li Q; Zhang X; Wang Y; Yang K; Zhang LW Toxicol Sci; 2017 Mar; 156(1):39-53. PubMed ID: 28013220 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives. Almela MJ; Torres PA; Lozano S; Herreros E Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329 [TBL] [Abstract][Full Text] [Related]
15. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Natalie M; Margino S; Erik H; Annelieke P; Geert V; Philippe V Toxicol In Vitro; 2009 Mar; 23(2):217-26. PubMed ID: 19101623 [TBL] [Abstract][Full Text] [Related]
16. A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis. Tomida T; Ishimura M; Iwaki M J Toxicol Sci; 2017; 42(5):641-650. PubMed ID: 28904299 [TBL] [Abstract][Full Text] [Related]
17. Detection of nanocarrier potentiation on drug induced phospholipidosis in cultured cells and primary hepatocyte spheroids by high content imaging and analysis. Zhang X; Yang L; Liu Y; Song Z; Zhao J; Chen D; Yu H; Li R; Wang Y; Yang K; Chen Y; Xia M; Zhang LW Toxicol Appl Pharmacol; 2018 Jun; 348():54-66. PubMed ID: 29678448 [TBL] [Abstract][Full Text] [Related]
18. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals. Jiang Z; Reilly J J Pharm Biomed Anal; 2012 Mar; 61():184-90. PubMed ID: 22200505 [TBL] [Abstract][Full Text] [Related]
19. Monitoring the accumulation of fluorescently labeled phospholipids in cell cultures provides an accurate screen for drugs that induce phospholipidosis. Nioi P; Pardo ID; Snyder RD Drug Chem Toxicol; 2008; 31(4):515-28. PubMed ID: 18850360 [TBL] [Abstract][Full Text] [Related]
20. In vitro assays and biomarkers for drug-induced phospholipidosis. Monteith DK; Morgan RE; Halstead B Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]